A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines

• Published in: Journal of translational medicine Vol. 11; no. 1; p. 128
• Main Authors: García-González, Paulina, Morales, Rodrigo, Hoyos, Lorena, Maggi, Jaxaira, Campos, Javier, Pesce, Bárbara, Gárate, David, Larrondo, Milton, González, Rodrigo, Soto, Lilian, Ramos, Verónica, Tobar, Pía, Molina, María Carmen, Pino-Lagos, Karina, Catalán, Diego, Aguillón, Juan Carlos
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24-05-2013; BioMed Central
• Subjects: Antigens; Autoimmunity; Biomarkers - metabolism; Blood banks; CD4-Positive T-Lymphocytes - cytology; Cell Differentiation; Cell Movement; Chemokines; Chemokines - metabolism; Cytokines - metabolism; Dendritic cells; Dendritic Cells - cytology; Dendritic Cells - drug effects; Dexamethasone; Dexamethasone - pharmacology; Flow Cytometry; Health aspects; Humans; Immune system; Ligands; Lipid A - analogs & derivatives; Lipid A - pharmacology; Lipids; Lymphocytes; Lymphoid tissue; Migration; Phenotype; Physiological aspects; Proteins; Quality control; Receptors, CCR7 - metabolism; Receptors, CXCR4 - metabolism; Rodents; Steroids; Studies; Technology application; California
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/1479-5876-11-128

Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for the design of protocols suitable for clinical applications, which means not only using safe products, but also working at defining specific biomarkers for TolDCs identification, developing shorter DCs differentiation methods and obtaining TolDCs with a stable phenotype. We describe here, a short-term protocol for TolDCs generation, which are characterized in terms of phenotypic markers, cytokines secretion profile, CD4+ T cell-stimulatory ability and migratory capacity.
TolDCs from healthy donors were generated by modulation with dexamethasone plus monophosphoryl lipid A (MPLA-tDCs). We performed an analysis of MPLA-tDCs in terms of yield, viability, morphology, phenotypic markers, cytokines secretion profile, stability, allogeneic and antigen-specific CD4+ T-cell stimulatory ability and migration capacity.
After a 5-day culture, MPLA-tDCs displayed reduced expression of costimulatory and maturation molecules together to an anti-inflammatory cytokines secretion profile, being able to maintain these tolerogenic features even after the engagement of CD40 by its cognate ligand. In addition, MPLA-tDCs exhibited reduced capabilities to stimulate allogeneic and antigen-specific CD4+ T cell proliferation, and induced an anti-inflammatory cytokine secretion pattern. Among potential tolerogenic markers studied, only TLR-2 was highly expressed in MPLA-tDCs when compared to mature and immature DCs. Remarkable, like mature DCs, MPLA-tDCs displayed a high CCR7 and CXCR4 expression, both chemokine receptors involved in migration to secondary lymphoid organs, and even more, in an in vitro assay they exhibited a high migration response towards CCL19 and CXCL12.
We describe a short-term protocol for TolDC generation, which confers them a stable phenotype and migratory capacity to lymphoid chemokines, essential features for TolDCs to be used as therapeutics for autoimmunity and prevention of graft rejection.